Mar 12, 2019 • 7:00 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
Mar 11, 2019 • 8:35 am EDT Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
Mar 7, 2019 • 8:00 am EST Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
Mar 4, 2019 • 9:15 am EST Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
Jan 30, 2019 • 7:30 am EST Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 25, 2019 • 9:01 am EST Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jan 3, 2019 • 10:01 am EST Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis